Table 4.
|
Placebo |
Apremilast BID |
||
---|---|---|---|---|
10 mg | 20 mg | 30 mg | ||
SF-36 BP with DLQI |
−0.45* |
−0.32* |
−0.52* |
−0.35* |
P<0.001 |
P=0.002 |
P<0.001 |
P=0.001 |
|
SF-36 VT with DLQI |
0.38* |
−0.18 |
−0.33* |
−0.23 |
P<0.001 |
P=NS |
P=0.003 |
P=0.040 |
|
SF-36 MCS with DLQI |
−0.57* |
−0.41* |
−0.42* |
−0.31* |
P<0.001 |
P<0.001 |
P<0.001 |
P=0.004 |
|
SF-36 BP with pruritus VAS |
−0.39* |
−0.27 |
−0.43* |
−0.30 |
P<0.001 |
P=0.013 |
P<0.001 |
P=0.005 |
|
SF-36 VT with pruritus VAS |
−0.36* |
0.01 |
−0.11 |
−0.23 |
P=0.001 |
P=NS |
P=NS |
P=0.034 |
|
SF-36 MCS with pruritus VAS |
−0.35* |
−0.21 |
−0.12 |
−0.35* |
P=0.001 | P=NS | P=NS | P=0.001 |
*Moderate correlations (r>0.30 and ≤0.60).
BP, Bodily Pain; DLQI, Dermatology Life Quality Index; MCS, mental component summary; SF-36, Short-Form 36 Health Survey; VAS, visual analog scale; VT, Vitality.